Stephen R. Byrn

发表

Predictive Approaches to Establishing, Understanding, and Communicating Risk with Emphasis on Early Development

Stephen R. Byrn, 2015 .

Human Capacity Building in Africa – The BIRS Model

Kari Clase, Stephen R. Byrn, Abigail Ekeigwe, 2019 .

Reducing time to market with : A science-based product management strategy

Kenneth R. Morris, Stephen R. Byrn, Shawn Comella, 2005 .

Advances in pharmaceutical materials and processing

Kinam Park, Kenneth R. Morris, Stephen R. Byrn, 1998 .

Efficient Laboratory Methods to Assess Risk and Design Formulations

Stephen R. Byrn, Roy Haskell, S. Byrn, 2015 .

Optimizing the physical form - opportunities and limitations.

Stephen R. Byrn, Jan-Olav Henck, S. Byrn, 2012, Drug discovery today. Technologies.

Solid-state pharmaceutical chemistry

David J.W. Grant, Stephen R. Byrn, Gregory A. Stephenson, 1994 .

Anhydrates and Hydrates of Olanzapine: Crystallization, Solid-State Characterization, and Structural Relationships

Stephen R. Byrn, G. Stephenson, S. Byrn, 2003 .

Acoustic levitation: recent developments and emerging opportunities in biomaterials research

Chris J. Benmore, Stephen R. Byrn, C. A. Rey, 2011, European Biophysics Journal.

Quality by Design and Process Analytical Technology for Pharmaceutical Manufacturing in the 21st Century

Stephen R. Byrn, 2008 .

Crystal structure, solid-state NMR spectra, and oxygen reactivity of five crystal forms of prednisolone tert-butylacetate

Stephen R. Byrn, P. Main, S. Byrn, 1988 .

A novel class of phenol–pyridine co-crystals for secondharmonic generation

Stephen R. Byrn, Doyle Britton, S. Byrn, 1997 .

SOLID-STATE ANALYSIS OF POLYMORPHIC, ISOMORPHIC, AND SOLVATED FORMS OF DIRITHROMYCIN

Stephen R. Byrn, Gregory A. Stephenson, Joseph G. Stowell, 1994 .